RxDoctor Payments Data

Liston Weatherly, APRN

Nurse Practitioner · Hartsville, SCNPI 1912413832

Payments from drug & device makers

$3,785in general payments, 2019–2025

Across 188 payments — averaging $20.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$439
  • AstraZeneca$407
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$392
  • Phathom Pharmaceuticals, Inc.$108
  • Lilly USA, LLC$97
  • plus $651 from 18 others

What the payments were for

  • Food & beverage$3,770100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,785 in reported general payments places this provider in the 90th percentile of 1,346 nurse practitioner providers in South Carolina.

See all nurse practitioner providers in South Carolina

Medicare billing

Part B allowed, 2024
$2,092
Medicare patients
61
Services billed
162

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide127$183,614
JardianceEmpagliflozin147$174,207
MounjaroTirzepatide107$151,726
FarxigaDapagliflozin Propanediol112$136,907
JanuviaSitagliptin Phosphate71$103,329
EliquisApixaban94$92,876
OzempicSemaglutide40$72,221
EntrestoSacubitril/Valsartan54$60,931
VraylarCariprazine Hcl40$56,509
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$49,708
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog25$18,976
VascepaIcosapent Ethyl30$17,800
Lantus SolostarInsulin Glargine,hum.Rec.Anlog95$13,521
Tresiba Flextouch U-200Insulin Degludec16$11,475
BrilintaTicagrelor19$9,172

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$97$335,340234 claims
AstraZenecaFarxiga, Brilinta$407$146,079131 claims
MerckJanuvia, Janumet Xr$28$109,77483 claims
PfizerEliquis$22$92,87694 claims
Novo NordiskOzempic$439$72,22140 claims
AbbVieVraylar, Linzess$1,690$65,60256 claims
NovartisEntresto$94$60,93154 claims
GSKTrelegy Ellipta$15$49,70847 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,346 nurse practitioner providers in South Carolina.

Other nurse practitioner in Hartsville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →